Clinical Trials Directory

Trials / Conditions / Condylomata Acuminata

Condylomata Acuminata

27 registered clinical trials studyying Condylomata Acuminata2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingPeginterferon α-2b Combined CO2 Laser in Condylomata Acuminata
NCT06430190
Zhangyu BuN/A
CompletedCavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
NCT06297187
Integra LifeSciences Corporation
Active Not RecruitingPlateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
NCT06197802
Xiamen University
CompletedIntralesional HPV Vaccine for Condylomata
NCT05087849
University of California, San FranciscoPhase 1 / Phase 2
Active Not RecruitingAn Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Ye
NCT05056402
Xiamen UniversityPhase 3
CompletedImmunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Col
NCT04782895
Xiamen UniversityPhase 3
Active Not RecruitingEfficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,5
NCT04537156
Xiamen UniversityPhase 3
UnknownEfficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genit
NCT03853785
Assiut UniversityPhase 3
CompletedA Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
NCT03981822
Verrica Pharmaceuticals Inc.Phase 2
CompletedImmunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT03935204
Xiamen UniversityPhase 2
CompletedSafety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT03813940
Xiamen UniversityPhase 1
CompletedSafety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females
NCT03546842
Merck Sharp & Dohme LLCPhase 3
TerminatedA Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital
NCT03158974
ViroXis CorporationPhase 2
UnknownSafety and Efficacy of Immune Therapy for Condyloma
NCT03158480
Shenzhen Second People's HospitalN/A
RecruitingCarbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma
NCT02520986
Zydolab - Institute of Cytology and Immune CytochemistryN/A
UnknownImmunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
NCT02710851
Jun ZhangPhase 2
CompletedSafety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
NCT02535104
Tamir Biotechnology, Inc.Phase 1 / Phase 2
CompletedSafety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
NCT02405520
Jun ZhangPhase 1
CompletedEfficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)
NCT01796821
G&E Herbal Biotechnology Co., LTDPhase 2
CompletedHuman Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
NCT01598779
University of Buenos Aires
CompletedSafety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
NCT01532102
Anaconda PharmaPhase 1 / Phase 2
UnknownEpidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile
NCT01483794
Universidad de Valparaiso
CompletedEvaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
NCT00973856
Cleveland Clinic Akron GeneralN/A
WithdrawnBroad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
NCT00365443
Merck Sharp & Dohme LLCPhase 2
CompletedAn Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Me
NCT00090285
Merck Sharp & Dohme LLCPhase 3
CompletedEfficacy and Safety Study of Polyphenon E to Treat External Genital Warts
NCT00449982
MediGenePhase 3
CompletedA Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
NCT02015260
University of AberdeenPhase 2